Tasly Pharmaceutical Group Co., Ltd (SHA:600535)

Market Cap	21.02B -7.5%
Revenue (ttm)	8.24B -3.1%
Net Income	1.10B +15.6%
EPS	0.74 +15.6%
Shares Out	1.49B
PE Ratio	19.02
Forward PE	15.70
Dividend	0.31 (2.20%)
Ex-Dividend Date	Oct 17, 2025

Volume	11,112,997
Average Volume	9,587,624
Open	14.20
Previous Close	14.07
Day's Range	14.14 - 14.35
52-Week Range	13.45 - 17.69
Beta	0.38
RSI	44.73
Earnings Date	Mar 20, 2026

About SHA:600535

Tasly Pharmaceutical Group Co., Ltd, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in China. The company offers prescription drugs covering various therapeutic areas, including cardiovascular-cerebrovascular, tumor immunity, digestion and metabolism, and neuroscience; over-the-counter drugs; modern TCM; biological drugs; and chemical drugs. It also engages in medical instruments, agriculture, and chain drugstore activities. The company was formerly known as Tianjin Tasly Pharmaceut...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 10,563
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600535

Financial Performance

In 2025, SHA:600535's revenue was 8.24 billion, a decrease of -3.08% compared to the previous year's 8.50 billion. Earnings were 1.10 billion, an increase of 15.63%.